-
Mashup Score: 0Investigation of Novel Management Strategies Continues to Mitigate Disease-Related Toxicities Across Hematologic Malignancies - 7 month(s) ago
Amy W. Zhou, MD, highlights the unique mechanism of action of the JAK1/2 and ACVR1 inhibitor momelotinib and the importance of ongoing investigations of JAK inhibitor combination therapies in myelofibrosis.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Events | Clinical Oncology Events & Registration | OncLive - 8 month(s) ago
The events section is a resource for health care providers to register for upcoming live events focused on cancer and treatment. Read more at OncLive.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Since July 2020, we've produced and hosted over 35 in-person and virtual Multiple Myeloma non-CE educational events. Find your next #MultipleMyeloma event here 👉 https://t.co/YfmFsljzIn #oncology #education #OncLiveIPC #OncLiveSOSS #doyouknowonclive https://t.co/abdD0XtXkK
-
-
Mashup Score: 0Events | Clinical Oncology Events & Registration | OncLive - 8 month(s) ago
The events section is a resource for health care providers to register for upcoming live events focused on cancer and treatment. Read more at OncLive.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Since July 2020, we've produced and hosted over 35 in-person and virtual Gastrointestinal Malignancies non-CE educational events. Find your next #GICancer event here 👉 https://t.co/cQNCYNufDp #oncology #education #OncLiveIPC #OncLiveSOSS #doyouknowonclive https://t.co/Y33cgISw2I
-
-
Mashup Score: 0Events | Clinical Oncology Events & Registration | OncLive - 8 month(s) ago
The events section is a resource for health care providers to register for upcoming live events focused on cancer and treatment. Read more at OncLive.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Since July 2020, we've produced and hosted over 50 in-person and virtual Breast Cancer non-CE educational events. Find your next #breastcancer event here 👉 https://t.co/oZPaBpMsOg #oncology #education #OncLiveIPC #OncLiveSOSS #doyouknowonclive https://t.co/b4L9LC28uy
-
-
Mashup Score: 0Events | Clinical Oncology Events & Registration | OncLive - 9 month(s) ago
The events section is a resource for health care providers to register for upcoming live events focused on cancer and treatment. Read more at OncLive.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Since July 2020, we've produced and hosted over 60 in-person and virtual Lung Cancer non-CE educational events. Find your next #lungcancer event here 👉 https://t.co/0DgLunh7zi #oncology #education #OncLiveIPC #OncLiveSOSS #doyouknowonclive https://t.co/5QT33jyzyo
-
-
Mashup Score: 2SUMMARY - OncLive/Institutional Perspectives in Cancer/Lung Cancer/August 17, 2023/CT - 9 month(s) ago
OncLive® Institutional Perspectives in Cancer: Disease State, Month Day, Year. Oncology Webinar features research and clinical advances in oncology.
Source: event.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join John V. Heymach, MD, PhD, of @MDAndersonNews as he chairs a Lung Cancer virtual event with Live Q&A on 8/17 at 6:00 PM CT! #OncLiveIPC Register: https://t.co/sav8mRtHqS https://t.co/BXw0XylzH9
-
-
Mashup Score: 0
Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Pedro C. Barata, MD, MSc, discusses the importance of exploring the facets of manipulating the microbiome to augment immunotherapy responses in RCC, and the promise of the bifidogenic live bacterial product CBM588. @PBarataMD @UHhospitals #OncLiveIPC #kcsm https://t.co/I0RJkYciMf
-
-
Mashup Score: 2
Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ADCs have redefined the parameters of HER2 expression required for HER2-directed therapy and restructured treatment sequencing for patients with HER2-positive breast cancer. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/qQeAzTWXZl https://t.co/TcaAighGoi
-
-
Mashup Score: 0
Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Erika P. Hamilton, MD, discusses the role of T-DXd in HER2+ and HER2-low breast cancer, the evolution of CDK4/6 inhibitors in HR+ disease, and how genetic testing supports precision medicine research. @ErikaHamilton9 @SarahCannonDocs #bcsm #OncLiveIPC https://t.co/KYnlhERuBx
-
-
Mashup Score: 0Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer - 10 month(s) ago
Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer @ErikaHamilton9 @PTarantinoMD @BurrisSkip @SarahCannonDocs @DanaFarber #bcsm #OncLiveIPC https://t.co/sPMkOpTjbz
-
Investigation of Novel Management Strategies Continues to Mitigate Disease-Related Toxicities Across Hematologic Malignancies @mpndoc @KSanfillipoMD @SanaSaifUrRehm @WUSTLmed @UChicago #OncLiveIPC #oncology https://t.co/LA5YrFkFfI